BrightSpring Third-Quarter Revenue Growth Reaccelerates

The Tip Desk · October 30, 2026 · 3 min read

Third-quarter revenue reached $4,213 million, up 26.4%, and the company issued full-year 2026 Adjusted EBITDA guidance of $850 million to $860 million.

BrightSpring Health Services (BTSG), a provider of home- and community-based health services, reported third-quarter net revenue of $4,213 million, up 26.4% from $3,334 million a year earlier, a faster pace than the 23.0% increase in the second quarter.

The company also issued full-year 2026 revenue and Adjusted EBITDA guidance, excluding the Community Living business it sold on March 30, 2026, and the effects of any future closed acquisitions.

Gross profit was $519 million, up 32.3% from $392 million a year earlier. Net income from continuing operations was $101 million, compared with $38 million in the third quarter of 2025. Adjusted EBITDA was $228 million, up 42.0% from $160 million a year earlier.

Pharmacy Solutions, the larger of the two reportable segments, generated $3,732 million of revenue, up 26% from $2,967 million a year earlier, after 22% growth in the second quarter. Segment EBITDA was $202 million, up 43% from $141 million.

The prescription volume that underpins that pharmacy mix was 10,949,875, up 2% from 10,793,219 a year earlier, after a 0% year-over-year change in the second quarter. Revenue per script was $340.86, up 24% from $274.89. Gross profit per script was $28.86, up 27% from $22.76.

Provider Services revenue was $481 million, up 31% from $367 million a year earlier. Segment EBITDA was $79 million, up 30% from $61 million. Home Health Care average daily census was 47,256, up 58% from 29,980 a year earlier. Rehab Care persons served were 7,574, up 9% from 6,932. Personal Care persons served were 16,320, up 1% from 16,134. Effective July 1, 2026, the company realigned Rehab in Motion from Rehab Care to Home Health Care and recast prior sub-segment information; the change did not affect consolidated or segment results.

Corporate costs were $53 million in the quarter. Total Segment EBITDA was $281 million, up 39% from $202 million a year earlier.

Leverage declined to 1.79x as of September 30, 2026, from 2.15x on June 30, 2026. Cash and cash equivalents were $717.8 million at quarter-end. Long-term debt, net of current portion, was $2.15 billion.

For the full year 2026, BrightSpring now expects revenue of $15,900 million to $16,125 million, or 23.2% to 24.9% growth versus 2025 results excluding Community Living. Pharmacy Segment revenue is guided at $14,000 million to $14,200 million, and Provider Segment revenue at $1,900 million to $1,925 million. Total Adjusted EBITDA is guided at $850 million to $860 million, or 37.6% to 39.3% growth. The company said the Amedisys and LHC branches acquisition is expected to contribute approximately $35 million in Adjusted EBITDA in 2026.

Chairman, President and Chief Executive Officer Jon Rousseau said third-quarter results reflected the team’s commitment to patient care and operational execution across Pharmacy and Provider, and that the company remained well-positioned to deliver durable growth in 2027 and beyond.